IL127564A0 - Solid oral dosage forms of valsartan - Google Patents

Solid oral dosage forms of valsartan

Info

Publication number: IL127564A0
Authority: IL; Israel
Prior art keywords: valsartan; dosage forms; oral dosage; solid oral; solid
Prior art date: 1996-06-27

Application number

IL12756497A

Other languages

English (en)

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-27

Filing date

1997-06-18

Publication date

1999-10-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10795969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL127564(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-06-18 Application filed by Novartis Ag filed Critical Novartis Ag

1999-10-28 Publication of IL127564A0 publication Critical patent/IL127564A0/xx

Links

239000004072 C09CA03 - Valsartan Substances 0.000 title 1
239000006186 oral dosage form Substances 0.000 title 1
239000007787 solid Substances 0.000 title 1
SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title 1
229960004699 valsartan Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Emergency Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IL12756497A 1996-06-27 1997-06-18 Solid oral dosage forms of valsartan IL127564A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9613470.5A GB9613470D0 (en)	1996-06-27	1996-06-27	Small solid oral dosage form
PCT/EP1997/003172 WO1997049394A2 (en)	1996-06-27	1997-06-18	Sold oral dosage forms of valsartan

Publications (1)

Publication Number	Publication Date
IL127564A0 true IL127564A0 (en)	1999-10-28

Family

ID=10795969

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL12756497A IL127564A0 (en)	1996-06-27	1997-06-18	Solid oral dosage forms of valsartan
IL195339A IL195339A0 (en)	1996-06-27	2008-11-17	Solid oral dosage forms of valsartan

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL195339A IL195339A0 (en)	1996-06-27	2008-11-17	Solid oral dosage forms of valsartan

Country Status (33)

Country	Link
US (3)	US6294197B1 (xx)
EP (7)	EP1774967A1 (xx)
JP (5)	JP2000506540A (xx)
KR (6)	KR20060079260A (xx)
CN (3)	CN1475207B (xx)
AR (2)	AR008618A1 (xx)
AT (3)	ATE446749T1 (xx)
BR (1)	BR9709956A (xx)
CA (2)	CA2259148C (xx)
CO (1)	CO4870755A1 (xx)
CY (1)	CY2553B1 (xx)
CZ (1)	CZ296850B6 (xx)
DE (3)	DE69738089T2 (xx)
DK (3)	DK1410797T3 (xx)
ES (3)	ES2335683T3 (xx)
GB (1)	GB9613470D0 (xx)
HK (2)	HK1019858A1 (xx)
HU (1)	HU229134B1 (xx)
ID (1)	ID17553A (xx)
IL (2)	IL127564A0 (xx)
MY (3)	MY156312A (xx)
NO (2)	NO317181B1 (xx)
NZ (2)	NZ333385A (xx)
PE (1)	PE87498A1 (xx)
PL (2)	PL188233B1 (xx)
PT (3)	PT1410797E (xx)
RU (5)	RU2203054C2 (xx)
SI (2)	SI1410797T1 (xx)
SK (1)	SK285902B6 (xx)
TR (1)	TR199802698T2 (xx)
TW (1)	TW473394B (xx)
WO (1)	WO1997049394A2 (xx)
ZA (1)	ZA975673B (xx)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9613470D0 (en)	1996-06-27	1996-08-28	Ciba Geigy Ag	Small solid oral dosage form
US20030045561A1 (en) *	2001-02-06	2003-03-06	Smithkline Beecham Corporation	Method of treating isolated systolic hypertension
PL342684A1 (en) *	1998-03-04	2001-07-02	Takeda Chemical Industries Ltd	Preperation featured by reterded release of aii antagonist, production and application of such preparation
PT1121103E (pt) *	1998-05-18	2007-02-28	Takeda Pharmaceutical	Comprimidos de desintegração oral compreendendo um benzimidazole
ID27664A (id) *	1998-07-10	2001-04-19	Novartis Ag	Kombinasi antihipersensitif dari valsartan dan penghalang saluran kalsium
NZ587909A (en)	1998-12-23	2012-05-25	Novartis Ag	Process of making a compressed tablets containing valsartan and microcrystalline cellulose
CN101011390A (zh)	1999-01-26	2007-08-08	诺瓦提斯公司	血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
RU2298405C2 (ru) *	1999-01-26	2007-05-10	Новартис Аг	Применение антагонистов рецептора ангиотензина ii для лечения острого инфаркта миокарда
CA2383252A1 (en) *	1999-08-24	2001-03-01	Medicure International Inc.	Treatment of cardiovascular related pathologies
DE10014416B4 (de) *	2000-03-24	2009-02-19	3M Espe Ag	Verwendung feinkörniger Pulver bzw. Pulvergemische zur Herstellung eines Mittels für supragingivales Pulverstrahlen
CA2311734C (en) *	2000-04-12	2011-03-08	Bristol-Myers Squibb Company	Flash-melt oral dosage formulation
US20020132839A1 (en) *	2000-06-22	2002-09-19	Ganter Sabina Maria	Tablet formulations comprising valsartan
PL358290A1 (en) *	2000-06-22	2004-08-09	Novartis Ag	Pharmaceutical compositions
AU2005200815B2 (en) *	2000-06-22	2008-01-17	Novartis Ag	Solid valsartan pharmaceutical compositions
AU2001289672B2 (en)	2000-07-19	2005-12-08	Novartis Ag	Valsartan salts
PE20020617A1 (es) *	2000-08-22	2002-08-05	Novartis Ag	Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
US20060089389A1 (en)	2000-08-22	2006-04-27	Malcolm Allison	Combination
US8168616B1 (en)	2000-11-17	2012-05-01	Novartis Ag	Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
EP1413315A4 (en) *	2001-08-03	2006-08-16	Takeda Pharmaceutical	DRUGS WITH CONTINUOUS RELEASE
GB0209265D0 (en)	2002-04-23	2002-06-05	Novartis Ag	Organic compounds
EG24716A (en) *	2002-05-17	2010-06-07	Novartis Ag	Combination of organic compounds
DE10230272A1 (de) *	2002-07-05	2004-01-22	Solvay Pharmaceuticals Gmbh	AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
EP1382334A1 (en) *	2002-07-11	2004-01-21	Université de Picardie Jules Verne	Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke
US7199144B2 (en) *	2003-04-21	2007-04-03	Teva Pharmaceuticals Industries, Ltd.	Process for the preparation of valsartan and intermediates thereof
EP1511739B1 (en) *	2003-03-17	2008-04-30	Teva Pharmaceutical Industries Ltd.	Polymorphs of valsartan
EP1950204A1 (en)	2003-03-17	2008-07-30	Teva Pharmaceutical Industries Ltd.	Amorphous form of valsartan
TW200505879A (en) *	2003-04-21	2005-02-16	Teva Pharma	Process for the preparation of valsartan
WO2004094391A2 (en) *	2003-04-21	2004-11-04	Teva Pharmaceutical Industries Ltd.	Process for the preparation of valsartan and intermediates thereof
JP4505859B2 (ja)	2003-08-08	2010-07-21	味の素株式会社	ナテグリニド含有製剤
SK50472005A3 (sk) *	2003-11-03	2005-09-08	Zentiva, A. S.	Tableta s obsahom valsartanu vyrobená priamym tabletovaním
GB0325605D0 (en) *	2003-11-03	2003-12-10	Novartis Ag	Combination of organic compounds
JP2005187793A (ja) *	2003-12-24	2005-07-14	Rohm & Haas Electronic Materials Llc	改良された接着剤
WO2005082329A2 (en) *	2004-02-19	2005-09-09	Ranbaxy Laboratories Limited	Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide
WO2005089720A1 (en) *	2004-03-10	2005-09-29	Ranbaxy Laboratories Limited	Valsartan tablets and the process for the preparation thereof
US7528258B2 (en)	2004-09-02	2009-05-05	Teva Pharmaceutical Industries Ltd	Preparation of olmesartan medoxomil
ES2525497T3 (es) *	2004-10-08	2015-10-09	Forward Pharma A/S	Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico
DE602005023193D1 (de) *	2004-10-15	2010-10-07	Suedzucker Ag	Verbessertes trommelcoating-verfahren
EP1674080A1 (en) *	2004-12-24	2006-06-28	KRKA, D.D., Novo Mesto	Solid pharmaceutical composition comprising valsartan
WO2006066961A1 (en) *	2004-12-24	2006-06-29	Krka, D.D., Novo Mesto	Solid pharmaceutical composition comprising valsartan
FR2882260A1 (fr) *	2005-02-21	2006-08-25	Flamel Technologies Sa	Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
EP2174658A1 (en) *	2005-05-31	2010-04-14	Mylan Laboratories, Inc	Compositions comprising nebivolol
US20070117987A1 (en) *	2005-07-05	2007-05-24	Viviana Braude	Process for preparing valsartan
GB0513888D0 (en) *	2005-07-06	2005-08-10	Btg Int Ltd	Core 2 GLCNAC-T Inhibitors II
US20080227836A1 (en) *	2005-10-31	2008-09-18	Lupin Ltd	Stable Solid Oral Dosage Forms of Valsartan
RU2309732C1 (ru)	2006-03-13	2007-11-10	Олег Ильич Эпштейн	Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
WO2007112288A2 (en) *	2006-03-23	2007-10-04	Mount Sinai School Of Medicine	Cardiovascular composition and use the same for the treatment of alzheimers disease
KR20090024241A (ko)	2006-06-06	2009-03-06	올레그 일리치 엡쉬테인	비만, 당뇨병 및 내당능 장애 관련 질병 치료용 약제
GB0612540D0 (en)	2006-06-23	2006-08-02	Novartis Ag	Galenical formulations of organic compounds
WO2008035364A2 (en) *	2006-06-23	2008-03-27	Usv Limited	Process for the preparation of micronized valsartan
EP1897537A1 (en) *	2006-09-04	2008-03-12	Novartis AG	Composition comprising an angiotensin II receptor antagonist
PE20081364A1 (es) *	2006-09-04	2008-12-04	Novartis Ag	Composicion farmaceutica que comprende valsartan
CN101534798B (zh) *	2006-10-30	2012-02-15	韩诺生物制约株式会社	包含噻嗪类和血管紧张素ⅱ受体阻断剂的控释药物组合物
WO2008064338A2 (en) *	2006-11-22	2008-05-29	Rubicon Research Pvt. Ltd.	Valsartan formulation for pulsatile delivery
WO2008120242A1 (en) *	2007-03-29	2008-10-09	Alembic Limited	Valsartan tablet formulations
TR200703568A1 (tr)	2007-05-24	2008-07-21	Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket�	Valsartan formülasyonları
CA2694516A1 (en) *	2007-07-31	2009-02-05	Cargill, Incorporated	Direct compressible dextrose
GB0715628D0 (en) *	2007-08-10	2007-09-19	Generics Uk Ltd	Solid valsartan composition
CN101396366B (zh) *	2007-09-25	2010-10-13	浙江华海药业股份有限公司	含缬沙坦的固体口服制剂及其制备方法
CA2698330A1 (en) *	2007-09-28	2009-04-09	Novartis Ag	Galenical formulations of organic compounds
KR20100091963A (ko) *	2007-10-09	2010-08-19	노파르티스 아게	발사르탄의 제약적 제형
NZ584686A (en)	2007-11-06	2013-03-28	Novartis Ag	Compositions of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate(S)-3'-methyl-2' -(pentanoyl{ 2 -(tetrazol-5-ylate)biphenyl-4'-ylmethyl} amino)butyrate]hemipentahydrate
EP2067470A1 (en) *	2007-12-03	2009-06-10	Laboratorios Lesvi, S.L.	Pharmaceutical compositions containing valsartan and process for its preparation
BRPI0821455A2 (pt) *	2007-12-31	2015-06-16	Lupin Ltd	Composições farmacêuticas de amlopidina e valsartan
EP2257288A1 (en) *	2008-02-28	2010-12-08	Novartis AG	Valsartan solid oral dosage forms and methods of making such formulations
US20090226516A1 (en) *	2008-03-04	2009-09-10	Pharma Pass Ii Llc	Sartan compositions
US20090226515A1 (en) *	2008-03-04	2009-09-10	Pharma Pass Ii Llc	Statin compositions
US20110117194A1 (en) *	2008-04-29	2011-05-19	Hanall Biopharma Co., Ltd.	Pharmaceutical formulation containing angiotensin-ii receptor blocker
AU2009257174A1 (en) *	2008-06-09	2009-12-17	Dimerix Bioscience Pty Ltd	Novel receptor hetero-dimers/-oligomers
KR101033975B1 (ko) *	2008-10-10	2011-05-11	이희엽	직접압축법을 이용한 발사르탄 함유 고형 경구 제형의 제조방법 및 이에 따라 제조된 고형 경구 제형
DE102008051783A1 (de)	2008-10-17	2010-04-22	Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg	Valsartan enthaltende Tablette
WO2010075347A2 (en)	2008-12-23	2010-07-01	Takeda Pharmaceutical Company Limited	Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
EP2405899A2 (en)	2009-03-11	2012-01-18	Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi	Valsartan formulations
WO2011027021A1 (en) *	2009-09-01	2011-03-10	Orion Corporation	A method for the treatment of hypertension
KR101084783B1 (ko) *	2009-09-01	2011-11-22	삼성에스디아이 주식회사	이차 전지 및 그의 제조 방법
ES2364011B1 (es)	2009-11-20	2013-01-24	Gp Pharm, S.A.	Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
CN101897675B (zh) *	2010-02-10	2012-11-21	温士顿医药股份有限公司	含有凡尔沙坦或其药学上可接受的盐的固体剂型口服医药组成物
EP2536396B1 (en)	2010-02-16	2016-08-10	KRKA, D.D., Novo Mesto	Process for the preparation of oral solid dosage forms comprising valsartan
AR083417A1 (es)	2010-10-14	2013-02-21	Novartis Ag	Composiciones farmaceuticas que contienen un dgat1 inhibidor
JP5882796B2 (ja)	2011-03-31	2016-03-09	キヤノン株式会社	振動体の駆動方法、振動装置、該振動装置を有する駆動装置、及び光学機器
GB201116993D0 (en) *	2011-10-03	2011-11-16	Ems Sa	Pharmaceutical compositions of antihypertensives
AU2012360935A1 (en)	2011-12-26	2014-07-17	Novartis Ag	Tablets and dry-coated agents
WO2013098576A1 (en)	2011-12-31	2013-07-04	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Immediate release pharmaceutical composition of valsartan
WO2013098578A1 (en)	2011-12-31	2013-07-04	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
JP6018420B2 (ja) *	2012-06-05	2016-11-02	ニプロ株式会社	アンジオテンシンｉｉ受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物
WO2014038895A1 (ko) *	2012-09-06	2014-03-13	한국콜마주식회사	발사르탄 함유 고형 경구제형 및 그 제조방법
JP2014062064A (ja) *	2012-09-21	2014-04-10	Ohara Yakuhin Kogyo Kk	バルサルタン含有錠剤の製造方法
JP6238831B2 (ja) *	2014-04-25	2017-11-29	沢井製薬株式会社	バルサルタン含有錠剤及びその製造方法
JP6141472B2 (ja) *	2016-03-02	2017-06-07	大原薬品工業株式会社	バルサルタン含有錠剤の製造方法
WO2018002673A1 (en)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Novel formulations of angiotensin ii receptor antagonists
JP2021528735A (ja)	2018-06-14	2021-10-21	アストラゼネカ・ユーケイ・リミテッドＡｓｔｒａＺｅｎｅｃａＵＫＬｉｍｉｔｅｄ	アンジオテンシンｉｉ受容体遮断薬医薬組成物による高血圧症の治療方法
EP4295839A1 (en)	2022-06-20	2023-12-27	KRKA, d.d., Novo mesto	Combination of valsartan and indapamide

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3200039A (en)	1962-05-28	1965-08-10	Pfizer & Co C	Non-granulated tablets with 20% sorbitol in a particle size of from about 100mu to about 2000mu
GB1422176A (en)	1973-05-05	1976-01-21	Beecham Group Ltd	Pharmaceutical tablets
AU528098B2 (en)	1978-11-16	1983-04-14	Beecham Group Plc	Analgesic tablet
US4353887A (en)	1979-08-16	1982-10-12	Ciba-Geigy Corporation	Divisible tablet having controlled and delayed release of the active substance
US4238485A (en) *	1979-10-29	1980-12-09	Merck & Co., Inc.	Novel pharmaceutical compositions
EP0070127A3 (en)	1981-07-10	1983-08-17	Beecham Group Plc	Tablets
US4543359A (en) *	1982-10-01	1985-09-24	Eaton Laboratories, Inc.	Treating cardiac arrhythmias with dantrolene sodium
HU187215B (en) *	1983-01-26	1985-11-28	Egyt Gyogyszervegyeszeti Gyar	Method for producing pharmaceutical product of high actor content and prolonged effect
US4609675A (en) *	1984-08-17	1986-09-02	The Upjohn Company	Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4743612A (en) *	1986-10-17	1988-05-10	Berlex Laboratories, Inc.	Prodrug derivatives of the cardiotonic agent 4-ethyl-1,3-dihydro-5-(4-(2-methyl-1H-imidazol-1-yl)benzoyl)-2H-imidazol-2-one, composition containing them, and method of using them to treat cardiac failure
DE3705055A1 (de) *	1987-02-18	1988-09-01	Boehringer Ingelheim Kg	Verwendung von 2-(3-fluor-4-methylphenylimino)-imidazolidin zur behandlung der koronaren herzkrankheit
JP2518854B2 (ja) *	1987-06-19	1996-07-31	旭化成工業株式会社	固形製剤の製法
DE3739779A1 (de) *	1987-11-24	1989-06-08	Beiersdorf Ag	Pharmazeutische praeparate
SE506179C2 (sv) *	1989-01-23	1997-11-17	Ciba Geigy Ag	Farmaceutisk lågkomposition av benazepril och ett tiaziddiuretikum
GB8909793D0 (en)	1989-04-28	1989-06-14	Beecham Group Plc	Pharmaceutical formulation
PH30484A (en) *	1990-02-19	1997-05-28	Ciba Geigy	Acy compounds pharmaceutical composition containing said compound and method of use thereof
WO1992005786A1 (en) *	1990-09-28	1992-04-16	Merck & Co., Inc.	Ibuprofen-diuretic combinations
JP3069458B2 (ja) *	1992-01-29	2000-07-24	武田薬品工業株式会社	口腔内崩壊型錠剤およびその製造法
ZA931063B (en)	1992-02-17	1993-09-23	Ciba Geigy	Treatment of glaucoma.
US5395627A (en) *	1992-09-04	1995-03-07	Akzo N.V.	Pharmaceutical granulate
IT1255522B (it) *	1992-09-24	1995-11-09	Ubaldo Conte	Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
AU5449194A (en)	1992-10-26	1994-05-24	Merck & Co., Inc.	Combinations of angiotensin-ii receptor antagonists and diuretics
AU5745394A (en)	1992-12-30	1994-08-15	Fmc Corporation	Readily available konjac glucomannan sustained release excipient
JP3057471B2 (ja) *	1993-06-07	2000-06-26	武田薬品工業株式会社	アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
US5464854A (en)	1993-11-11	1995-11-07	Depadova; Anathony S.	Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S.
AT401871B (de) *	1994-01-28	1996-12-27	Gebro Broschek Gmbh	Verfahren zur herstellung von s(+)-ibuprofen- partikeln mit verbesserten fliesseigenschaften und deren verwendung zur arzneimittelherstellung
JP3534130B2 (ja) *	1994-03-01	2004-06-07	旭化成ケミカルズ株式会社	医薬品組成物
GB9404010D0 (en) *	1994-03-02	1994-04-20	Opt Tel Services Limited	Telephone dialling monitoring and route selecting apparatus
HUT76542A (en)	1994-03-17	1997-09-29	Ciba Geigy Ag	Use of valsartan for the preparation of pharmaceutical composition serving for the treatment of diabetic nephropathy
GB9408117D0 (en)	1994-04-23	1994-06-15	Smithkline Beecham Corp	Pharmaceutical formulations
DE19502065C2 (de) *	1995-01-14	1996-05-02	Prophyta Biolog Pflanzenschutz	Pilzisolat mit fungizider Wirkung
US5994348A (en) *	1995-06-07	1999-11-30	Sanofi	Pharmaceutical compositions containing irbesartan
FR2735365B1 (fr) *	1995-06-14	1997-09-05	Sanofi Sa	Utilisation d'un antagoniste de l'angiotensine ii et d'un derive du benzofurane pour la preparation d'un medicament utile dans le traitement des affections cardiovasculaires
GB9613470D0 (en) *	1996-06-27	1996-08-28	Ciba Geigy Ag	Small solid oral dosage form
JP2011123241A (ja) *	2009-12-10	2011-06-23	Canon Inc	撮影システム

1996
- 1996-06-27 GB GBGB9613470.5A patent/GB9613470D0/en active Pending
1997
- 1997-06-14 MY MYPI20093392A patent/MY156312A/en unknown
- 1997-06-14 MY MYPI20041863A patent/MY146868A/en unknown
- 1997-06-14 MY MYPI97002679A patent/MY123149A/en unknown
- 1997-06-18 CN CN031466788A patent/CN1475207B/zh not_active Expired - Lifetime
- 1997-06-18 EP EP06126829A patent/EP1774967A1/en not_active Withdrawn
- 1997-06-18 KR KR1020067011260A patent/KR20060079260A/ko not_active Application Discontinuation
- 1997-06-18 CN CNB971958912A patent/CN1133427C/zh not_active Expired - Lifetime
- 1997-06-18 KR KR1020097017936A patent/KR101161283B1/ko not_active IP Right Cessation
- 1997-06-18 IL IL12756497A patent/IL127564A0/xx unknown
- 1997-06-18 DK DK03027840T patent/DK1410797T3/da active
- 1997-06-18 DK DK06126819.9T patent/DK1767206T3/da active
- 1997-06-18 HU HU0203374A patent/HU229134B1/hu not_active IP Right Cessation
- 1997-06-18 SI SI9730773T patent/SI1410797T1/sl unknown
- 1997-06-18 DE DE69738089T patent/DE69738089T2/de not_active Expired - Lifetime
- 1997-06-18 SK SK1784-98A patent/SK285902B6/sk not_active IP Right Cessation
- 1997-06-18 SI SI9730686T patent/SI0914119T1/xx unknown
- 1997-06-18 ES ES06126819T patent/ES2335683T3/es not_active Expired - Lifetime
- 1997-06-18 PT PT03027840T patent/PT1410797E/pt unknown
- 1997-06-18 KR KR1020117011286A patent/KR101208430B1/ko not_active IP Right Cessation
- 1997-06-18 KR KR1020057015071A patent/KR100792389B1/ko not_active IP Right Cessation
- 1997-06-18 CA CA002259148A patent/CA2259148C/en not_active Expired - Fee Related
- 1997-06-18 PL PL97330709A patent/PL188233B1/pl not_active IP Right Cessation
- 1997-06-18 AT AT06126819T patent/ATE446749T1/de active
- 1997-06-18 CA CA2673462A patent/CA2673462C/en not_active Expired - Fee Related
- 1997-06-18 PL PL97363524A patent/PL188271B1/pl unknown
- 1997-06-18 AT AT97929209T patent/ATE276750T1/de active
- 1997-06-18 NZ NZ333385A patent/NZ333385A/xx not_active IP Right Cessation
- 1997-06-18 EP EP03027840A patent/EP1410797B1/en not_active Revoked
- 1997-06-18 BR BR9709956A patent/BR9709956A/pt not_active Application Discontinuation
- 1997-06-18 KR KR1020087000538A patent/KR20080014149A/ko active Search and Examination
- 1997-06-18 EP EP97929209A patent/EP0914119B1/en not_active Expired - Lifetime
- 1997-06-18 EP EP06126819A patent/EP1767206B1/en not_active Revoked
- 1997-06-18 JP JP10502269A patent/JP2000506540A/ja active Pending
- 1997-06-18 DE DE69730834T patent/DE69730834T2/de not_active Expired - Lifetime
- 1997-06-18 RU RU99101056/14A patent/RU2203054C2/ru active IP Right Maintenance
- 1997-06-18 KR KR1019980710521A patent/KR100618038B1/ko not_active IP Right Cessation
- 1997-06-18 EP EP06126834A patent/EP1776953A1/en not_active Withdrawn
- 1997-06-18 EP EP09001681A patent/EP2055301A1/en not_active Withdrawn
- 1997-06-18 WO PCT/EP1997/003172 patent/WO1997049394A2/en active Search and Examination
- 1997-06-18 DK DK97929209T patent/DK0914119T3/da active
- 1997-06-18 TR TR1998/02698T patent/TR199802698T2/xx unknown
- 1997-06-18 US US09/202,805 patent/US6294197B1/en not_active Expired - Lifetime
- 1997-06-18 PT PT97929209T patent/PT914119E/pt unknown
- 1997-06-18 ES ES97929209T patent/ES2231873T3/es not_active Expired - Lifetime
- 1997-06-18 PT PT06126819T patent/PT1767206E/pt unknown
- 1997-06-18 EP EP06126838A patent/EP1767207A3/en not_active Withdrawn
- 1997-06-18 ES ES03027840T patent/ES2290400T3/es not_active Expired - Lifetime
- 1997-06-18 RU RU99101056/63D patent/RU2294743C2/ru not_active IP Right Cessation
- 1997-06-18 CN CN2006100999105A patent/CN1951372B/zh not_active Expired - Lifetime
- 1997-06-18 AT AT03027840T patent/ATE371449T1/de active
- 1997-06-18 DE DE69739642T patent/DE69739642D1/de not_active Expired - Lifetime
- 1997-06-18 CZ CZ0426998A patent/CZ296850B6/cs not_active IP Right Cessation
- 1997-06-23 CO CO97034775A patent/CO4870755A1/es unknown
- 1997-06-24 PE PE1997000539A patent/PE87498A1/es not_active IP Right Cessation
- 1997-06-25 AR ARP970102790A patent/AR008618A1/es active IP Right Grant
- 1997-06-26 ID IDP972207A patent/ID17553A/id unknown
- 1997-06-26 ZA ZA9705673A patent/ZA975673B/xx unknown
- 1997-09-09 TW TW086113018A patent/TW473394B/zh not_active IP Right Cessation
1998
- 1998-12-22 NO NO19986056A patent/NO317181B1/no not_active IP Right Cessation
1999
- 1999-11-09 HK HK99105148A patent/HK1019858A1/xx not_active IP Right Cessation
2001
- 2001-08-01 US US09/920,159 patent/US6485745B1/en not_active Expired - Fee Related
2002
- 2002-09-20 US US10/251,009 patent/US6858228B2/en not_active Expired - Fee Related
2003
- 2003-01-23 JP JP2003014987A patent/JP2003231634A/ja not_active Withdrawn
- 2003-02-21 NZ NZ524346A patent/NZ524346A/en not_active IP Right Cessation
2004
- 2004-03-26 NO NO20041287A patent/NO331739B1/no not_active IP Right Cessation
- 2004-05-25 HK HK04103718.1A patent/HK1060700A1/xx not_active IP Right Cessation
2006
- 2006-03-21 CY CY0600007A patent/CY2553B1/xx unknown
2007
- 2007-01-10 RU RU2007100200/15A patent/RU2453306C2/ru not_active IP Right Cessation
- 2007-02-06 AR ARP070100474A patent/AR059324A2/es not_active Application Discontinuation
- 2007-06-28 JP JP2007170267A patent/JP4969338B2/ja not_active Expired - Lifetime
2008
- 2008-11-17 IL IL195339A patent/IL195339A0/en unknown
2009
- 2009-04-27 RU RU2009115778/15A patent/RU2009115778A/ru unknown
2011
- 2011-12-09 JP JP2011270429A patent/JP2012051948A/ja not_active Withdrawn
2013
- 2013-03-26 RU RU2013113610/15A patent/RU2013113610A/ru not_active Application Discontinuation
- 2013-10-25 JP JP2013221985A patent/JP2014012747A/ja active Pending

Also Published As

Publication number	Publication date
EP2055301A1 (en)	2009-05-06
DK1767206T3 (da)	2010-01-25
HUP0203374A3 (en)	2004-06-28
SK285902B6 (sk)	2007-10-04
DE69730834T2 (de)	2005-10-06
EP1767207A2 (en)	2007-03-28
CA2259148A1 (en)	1997-12-31
DK0914119T3 (da)	2005-01-31
JP2012051948A (ja)	2012-03-15
EP1767206A2 (en)	2007-03-28
IL195339A0 (en)	2009-08-03
CN1951372B (zh)	2011-03-23
HK1019858A1 (en)	2000-06-09
DE69739642D1 (de)	2009-12-10
SK178498A3 (en)	1999-06-11
JP2000506540A (ja)	2000-05-30
ATE446749T1 (de)	2009-11-15
KR20110063587A (ko)	2011-06-10
ATE371449T1 (de)	2007-09-15
PL188233B1 (pl)	2004-12-31
HK1060700A1 (en)	2004-08-20
EP1410797B1 (en)	2007-08-29
TW473394B (en)	2002-01-21
KR20000022111A (ko)	2000-04-25
KR20090099020A (ko)	2009-09-18
EP0914119B1 (en)	2004-09-22
MY156312A (en)	2016-01-29
SI1410797T1 (sl)	2008-08-31
DE69738089T2 (de)	2008-05-21
KR100618038B1 (ko)	2006-11-30
PL188271B1 (pl)	2005-01-31
KR20060079260A (ko)	2006-07-05
CO4870755A1 (es)	1999-12-27
KR100792389B1 (ko)	2008-01-08
MY123149A (en)	2006-05-31
ATE276750T1 (de)	2004-10-15
PE87498A1 (es)	1998-12-21
KR20080014149A (ko)	2008-02-13
RU2203054C2 (ru)	2003-04-27
CZ296850B6 (cs)	2006-07-12
CN1475207B (zh)	2010-09-29
CZ426998A3 (cs)	1999-03-17
WO1997049394A3 (en)	2001-12-20
RU2013113610A (ru)	2014-10-10
EP1776953A1 (en)	2007-04-25
CY2553B1 (en)	2008-07-02
EP1410797A1 (en)	2004-04-21
MY146868A (en)	2012-09-28
US20030035832A1 (en)	2003-02-20
US6485745B1 (en)	2002-11-26
DE69738089D1 (de)	2007-10-11
CA2673462A1 (en)	1997-12-31
ID17553A (id)	1998-01-08
US6858228B2 (en)	2005-02-22
WO1997049394A2 (en)	1997-12-31
EP1767206B1 (en)	2009-10-28
EP1767206A3 (en)	2007-04-18
ES2335683T3 (es)	2010-03-31
KR20050092054A (ko)	2005-09-16
AU3340297A (en)	1998-01-14
GB9613470D0 (en)	1996-08-28
CN1232394A (zh)	1999-10-20
RU2453306C2 (ru)	2012-06-20
NO20041287L (no)	2004-03-26
NO986056L (no)	1998-12-22
EP1767207A3 (en)	2007-04-18
NZ524346A (en)	2004-09-24
RU2294743C2 (ru)	2007-03-10
NO331739B1 (no)	2012-03-12
JP2014012747A (ja)	2014-01-23
SI0914119T1 (en)	2005-04-30
CN1133427C (zh)	2004-01-07
PL330709A1 (en)	1999-05-24
JP2003231634A (ja)	2003-08-19
NO317181B1 (no)	2004-09-06
PT914119E (pt)	2005-02-28
KR101161283B1 (ko)	2012-07-02
EP1774967A1 (en)	2007-04-18
CN1951372A (zh)	2007-04-25
JP4969338B2 (ja)	2012-07-04
ES2290400T3 (es)	2008-02-16
KR101208430B1 (ko)	2012-12-05
JP2007238637A (ja)	2007-09-20
CN1475207A (zh)	2004-02-18
RU2009115778A (ru)	2010-11-10
US6294197B1 (en)	2001-09-25
DE69730834D1 (de)	2004-10-28
BR9709956A (pt)	1999-08-10
HUP0203374A2 (hu)	2004-05-28
AR008618A1 (es)	2000-02-09
PT1767206E (pt)	2010-01-27
AR059324A2 (es)	2008-03-26
ZA975673B (en)	1997-12-29
TR199802698T2 (xx)	1999-04-21
RU2007100200A (ru)	2008-07-20
ES2231873T3 (es)	2005-05-16
NO986056D0 (no)	1998-12-22
HU229134B1 (en)	2013-08-28
NZ333385A (en)	2000-09-29
CA2259148C (en)	2009-09-29
AU724998B2 (en)	2000-10-05
CA2673462C (en)	2011-10-04
EP0914119A3 (en)	2002-03-06
PT1410797E (pt)	2007-12-03
EP0914119A2 (en)	1999-05-12
DK1410797T3 (da)	2007-10-15

Publication	Publication Date	Title
CY2553B1 (en)	2008-07-02	Solid oral dosage forms of valsartan
HUP9903407A3 (en)	2000-11-28	Oral pharmaceutical preparation containing ibandronat
HUP9901454A3 (en)	2001-04-28	Dosage form of ibuprofen
EP1020193A4 (en)	2006-05-24	ORAL PREPARATION
EG24077A (en)	2008-05-11	Oral 2-methyl-thieno-benzodiazepine formulation
HUP9603064A2 (en)	1997-08-28	New oral pharmaceutical dosage form
HUP9802913A3 (en)	2000-06-28	Bioadhesive solid dosage form
PL341428A1 (en)	2001-04-09	Oral pharmacological dosage form of prolonged release type
HUP0003757A3 (en)	2001-07-30	Oral pharmaceutical compositions of levosimendan
IL138192A0 (en)	2001-11-25	Controlled release oral dosage forms
ZA976189B (en)	1999-01-11	Oral pharmaceutical combinations
PL340456A1 (en)	2001-02-12	Novel oral dosage form of carvedilol
HUP9904345A3 (en)	2000-11-28	Oral contraceptive
GB9600390D0 (en)	1996-03-13	Preparation of tablets
GB9618964D0 (en)	1996-10-23	Oral composition
GB9411594D0 (en)	1994-08-03	Demagnetisation of materials
AU724998C (en)	2013-05-23	Solid oral dosage forms of valsartan
ZA974125B (en)	1998-11-13	Oral pharmaceutical compositions
IL126588A0 (en)	1999-08-17	Oral dosage forms of azithromycin for improved food-compatibility
GB9707576D0 (en)	1997-06-04	Enhancement of oral hygiene
GB9407647D0 (en)	1994-06-08	Oral medicament
ZA976144B (en)	1999-01-11	Oral pharmaceutical compositions
AUPN996996A0 (en)	1996-06-13	Treatment of oral conditions
IL105714A0 (en)	1993-09-22	Oral dosage forms of risedronate
GB9720312D0 (en)	1997-11-26	Oral hygiene system